Cancerify Logo
Log inSign up
Back to clinical trials
RecruitingInterventionalPhase 2/Phase 3

Randomized Phase II/III Trial of Adjuvant Radiation Therapy With Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and Neck

NCT ID: NCT01810913Sponsor: National Cancer Institute (NCI)Last updated: 2026-06-17

Summary

This phase II/III trial studies how well radiation therapy works when given together with cisplatin, docetaxel, cetuximab, and/or atezolizumab after surgery in treating patients with high-risk stage III-IV head and neck cancer the begins in the thin, flat cells (squamous cell). Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. Drugs used in chemotherapy, such as cisplatin and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Cetuximab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. The purpose of this study is to compare the usual treatment (radiation therapy with cisplatin chemotherapy) to using radiation therapy with docetaxel and cetuximab chemotherapy, and using the usual treatment plus an immunotherapy drug, atezolizumab.

Detailed description

PRIMARY OBJECTIVES: I. To select the better docetaxel-based experimental arm to improve disease-free survival (DFS) over the control arm of radiation and cisplatin. (Phase II) (COMPLETE AS OF 20-MAR-2020) II. To determine if the combination of docetaxel-cetuximab and intensity-modulated radiation therapy (IMRT) is superior in terms of overall survival (OS) compared to standard cisplatin and IMRT in the adjuvant treatment of pathologic high risk, human papillomavirus (HPV)-negative head and neck squamous cell carcinoma (HNSCC). (Phase III) III. To determine if the combination of atezolizumab, cisplatin, and IMRT is superior in terms of OS compared to standard cisplatin and IMRT in the adjuvant treatment of pathologic high risk, HPV-negative HNSCC. (Phase III) SECONDARY OBJECTIVES: I. To compare disease-free survival (DFS) between each experimental arm and the control arm. (Phase III) II. To determine whether each experimental arm improves local-regional disease control and the rate of distant metastasis. (Phase III) III. To compare acute toxicity profiles between each experimental arm and the control arm. (Phase III) IV. To compare late toxicity profiles at 1, 3, and 5 years after treatment. (Phase III) V. To assess long term DFS and OS between each experimental arm and the control arm. (Phase III) VI. To compare symptom burden, as measured by the MD Anderson Symptom Inventory - Head and Neck (MDASI-HN) (primary patient reported outcome \[PRO\]), and quality of life, as measured by the Functional Assessment of Cancer Therapy - Head and Neck (FACT-H\&N) (secondary PRO), between each experimental arm and the control arm. (Phase III) EXPLORATORY OBJECTIVE: I. To collect blood and tissue specimens for future translational research. (Phase III) OUTLINE: Patients are randomized to 1 of 3 arms - Phase II (Arms 1, 2 or 3) and for Phase III (Arms 1, 3 or 4). ARM 1: Patients undergo intensity modulated radiation therapy (IMRT) once daily (QD) five days a week for 6 weeks and receive concurrent cisplatin intravenously (IV) over 1-2 hours once weekly for 6 weeks in the absence of disease progression or unacceptable toxicity. ARM 2: Patients undergo IMRT as in Arm I and receive concurrent docetaxel IV over 60 minutes once weekly for 6 weeks in the absence of disease progression or unacceptable toxicity. (CLOSED AS OF 20-MAR-2020) ARM 3: Patients receive cetuximab IV over 120 minutes on week 1 and over 60 minutes once weekly on weeks 2-7. Patients undergo IMRT as in Arm I and concurrently receive docetaxel once weekly for 6 weeks in the absence of disease progression or unacceptable toxicity. ARM 4: Patients undergo IMRT QD five days a week for 6 weeks and receive concurrent cisplatin IV over 1-2 hours once weekly for 6 weeks. Starting 1 week before IMRT, patients also receive atezolizumab IV over 30-60 minutes every 3 weeks for up to 8 doses (weeks -1, 3, 6, 9, 12, 15, 18, and 21) in the absence of disease progression and unacceptable toxicity. All patients undergo collection of blood samples during screening and throughout the study and may undergo computed tomography (CT) scans and/or magnetic resonance imaging (MRI) and biopsy as clinically indicated on study. After completion of study treatment, patients are followed up at 1 and 3 months, every 3 months for 2 years, every 6 months for 3 years, and then annually thereafter.

Arms & interventions

  • DrugAtezolizumab

    Given IV

  • ProcedureBiopsy Procedure

    Undergo biopsy

  • ProcedureBiospecimen Collection

    Undergo collection of blood

  • BiologicalCetuximab

    Given IV

  • DrugCisplatin

    Given IV

  • ProcedureComputed Tomography

    Undergo CT

  • DrugDocetaxel

    Given IV

  • RadiationIntensity-Modulated Radiation Therapy

    Undergo IMRT

  • ProcedureMagnetic Resonance Imaging

    Undergo MRI

  • OtherSurvey Administration

    Ancillary studies

Outcome measures

Primary

  • Disease-free survival (Phase II)

    Estimated using the Kaplan-Meier method for each arm. Their distributions will be compared between treatment arms with a one-sided log rank test.

    Time frame: From date of randomization until date of local-regional recurrence, distant metastasis or death due to any cause, assessed up to 7 years

  • Overall survival (Phase III)

    Estimated using the Kaplan-Meier method for each arm. Their distributions will be compared between treatment arms with a one-sided log rank test. Multivariate analysis will be performed using the Cox proportional hazards model.

    Time frame: From date of randomization to death due to any cause, assessed up to 7 years

Secondary

  • Local-regional failure

    Time frame: From date of randomization until date of local-regional recurrence, assessed up to 7 years

  • Distant metastasis

    Time frame: From date of randomization to date of distant metastasis, assessed up to 7 years

  • Toxicity

    Time frame: From start of treatment to death or last follow-up

  • Patient-reported outcome, symptom burden

    Time frame: Time from randomization to a first recovery within at least one MID unit of total symptom severity compared to the baseline (reference) score

  • Quality of life

    Time frame: Baseline and 1 year post radiation therapy

Eligibility criteria

Sex: AllAge: 18 Years and olderHealthy volunteers: No
Inclusion Criteria: * PHASE II INCLUSION CRITERIA (COMPLETE AS OF 20-MAR-2020) * Pathologically (histologically or cytologically) proven diagnosis of head and neck squamous cell carcinoma (HNSCC) involving the oral cavity (excluding lips), oropharynx (p16 negative), larynx, or hypopharynx * Patients must have undergone gross total surgical resection of high-risk oral cavity, oropharynx (p16 negative), larynx, or hypopharynx within 63 days prior to registration; Note: patients may have biopsy under general anesthesia in an operating room followed by definitive ablative cancer surgery representing gross total resection; the gross total resection has to be done within 63 days prior to registration; if, however, patients have ablative resection but shortly recur or are determined to have persisting disease requiring re-resection to achieve gross total resection, then the patient is not eligible * Patients must have at least 1 of the following high-risk pathologic features: extracapsular nodal extension or invasive cancer at the primary tumor resection margin (tumor on ink) * Pathologic stage III or IV HNSCC, including no distant metastases, based upon the following minimum diagnostic workup: * General history and physical examination by a radiation oncologist and/or medical oncologist within 84 days prior to registration; * Examination by an ear nose throat (ENT) or head \& neck surgeon prior to surgery; a laryngopharyngoscopy (mirror and/or fiber optic and/or direct procedure), if appropriate, is recommended but not required; intra-operative examination is acceptable documentation * Pre-operative (op) Imaging of the head and neck: A neck computed tomography (CT) (with contrast) or CT/positron emission tomography (PET) (with contrast) and/or an magnetic resonance imaging (MRI) of the neck (T1 with gadolinium and T2) within 84 days prior to surgery; Note: this imaging data (diagnostic pre-operative scan showing gross disease) is to be submitted in Digital Imaging and Communications in Medicine (DICOM) format via TRIAD; the report is to be uploaded into Rave * Chest CT scan (with or without contrast) or CT/PET that includes the chest (with or without contrast) either within 84 days prior to surgery or within 120 days prior to registration; Note: if the CT/PET with or without contrast is done within 84 days prior to surgery, it fulfills the chest imaging requirement * Zubrod performance status of 0-1 within 14 days prior to registration * Age \>= 18 * Absolute granulocyte count (AGC) \>= 1,500 cells/mm\^3 (obtained within 14 days prior to registration on study) * Platelets \>= 100,000 cells/mm\^3 (obtained within 14 days prior to registration on study) * Hemoglobin \>= 8.0 g/dl (Note: the use of transfusion or other intervention to achieve hemoglobin \[Hgb\] \>= 8.0 g/dl is acceptable) * Total bilirubin \< 2 x institutional upper limit of normal (ULN) within 14 days prior to registration * Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \< 3 x institutional ULN within 14 days prior to registration * Serum creatinine institutional ULN within 14 days prior to registration or; creatinine clearance (CC) \>= 50 ml/min within 14 days prior to registration determined by 24-hour collection or estimated by Cockcroft-Gault formula * Negative urine or serum pregnancy test within 14 days prior to registration for women of childbearing potential * The following assessments are required within 14 days prior to registration: sodium (Na), potassium (K), chloride (Cl), glucose, calcium (Ca), magnesium (Mg), and albumin; Note: patients with an initial magnesium \< 0.5 mmol/L (1.2 mg/dl) may receive corrective magnesium supplementation but should continue to receive either prophylactic weekly infusion of magnesium and/or oral magnesium supplementation (e.g., magnesium oxide) at the investigator's discretion * Patients with feeding tubes are eligible for the study * Women of childbearing potential and male participants who are sexually active must agree to use a medically effective means of birth control * Patient must provide study specific informed consent prior to study entry, including consent for mandatory tissue submission for epidermal growth factor receptor (EGFR) analysis and for oropharyngeal cancer patients, human papilloma virus (HPV) analysis * PHASE III: Pathologically (histologically or cytologically) proven diagnosis of head and neck squamous cell carcinoma (HNSCC) involving the oral cavity (excluding lips), oropharynx (p16 negative), larynx, or hypopharynx * PHASE III: Patients with oropharyngeal cancer must have p16-negative based on central review prior to Step 2 registration. All patients with oropharyngeal primary must consent for mandatory tissue submission for central p16 confirmation * PHASE III: Patients must have undergone gross total surgical resection of high-risk oral cavity, oropharynx (p16 negative), larynx, or hypopharynx within 63 days prior to registration * Note: Patients may have biopsy under general anesthesia in an operating room followed by definitive ablative cancer surgery representing gross total resection. The gross total resection has to be done within 63 days prior to registration. If, however, patients have ablative resection but shortly recur or are determined to have persisting disease requiring re-resection to achieve gross total resection, then the patient is not eligible * PHASE III: Patients must have at least 1 of the following high-risk pathologic features: extracapsular nodal extension or invasive cancer at the primary tumor resection margin (tumor on ink or tumor in a final separately submitted margin) * PHASE III: Pathologic stage III or IV HNSCC (American Joint Committee on Cancer \[AJCC\] 7th edition), including no distant metastases, based upon the following minimum diagnostic workup: * General history and physical examination by a radiation oncologist or medical oncologist within 84 days prior to registration; * Examination by an ENT or head \& neck surgeon prior to surgery; a laryngopharyngoscopy (mirror or fiberoptic or direct procedure), if appropriate, is recommended but not required. Intra-operative examination is acceptable documentation. * Pre-op Imaging of the head and neck: A neck CT (with contrast and of diagnostic quality) or PET/CT (with contrast and of diagnostic quality) and/or an MRI of the neck of diagnostic quality (T1 with gadolinium and T2) within 84 days prior to surgery; Note: this imaging data (diagnostic pre-operative scan showing gross disease) is to be submitted in DICOM format via TRIAD. The report is to be uploaded into Rave. * Chest CT scan (with or without contrast) or PET/CT that includes the chest (with or without contrast) either within 84 days prior to surgery or within 120 days prior to registration; Note: If the PET/CT with or without contrast is done within 84 days prior to surgery, it fulfills the chest imaging requirement * PHASE III: Zubrod performance status of 0-1 within 14 days prior to registration * PHASE III: Age \>= 18 * PHASE III: Leukocytes \>= 2,500 cells/mm\^3 (obtained within 14 days prior to registration on study) * PHASE III: Absolute neutrophil count (ANC) \>= 1,500 cells/mm\^3 (obtained within 14 days prior to registration on study) * PHASE III: Platelets \>= 100,000 cells/mm\^3 (obtained within 14 days prior to registration on study) * PHASE III: Hemoglobin \>= 8.0 g/dL (Note: The use of transfusion or other intervention to achieve Hgb \>= 8.0 g/dL is acceptable) (obtained within 14 days prior to registration on study) * PHASE III: Total bilirubin =\< 1.5 x institutional upper limit of normal (ULN) (however, patients with known Gilbert disease who have serum bilirubin level =\< 3 x institutional ULN may be enrolled) (within 14 days prior to registration) * PHASE III: AST or ALT =\< 3 x institutional ULN (within 14 days prior to registration) * PHASE III: Alkaline phosphatase =\< 2.5 x institutional ULN (within 14 days prior to registration) * PHASE III: Creatinine clearance (CrCl) \>= 50 mL/min within 14 days prior to registration determined by 24-hour collection or estimated by Cockcroft-Gault formula * PHASE III: Patients with feeding tubes are eligible for the study * PHASE III: Negative urine or serum pregnancy test within 14 days prior to registration for women of childbearing potential * PHASE III: All patients must provide study specific informed consent prior to study entry * PHASE III: Patients positive for human immunodeficiency virus (HIV) are allowed on study, but HIV-positive patients must have: * A stable regimen of highly active anti-retroviral therapy (HAART); * No requirement for concurrent antibiotics or antifungal agents for the prevention of opportunistic infections; * A CD4 count above 250 cells/mcL and an undetectable HIV viral load on standard polymerase chain reaction (PCR)-based tests Exclusion Criteria: * PHASE II EXCLUSION CRITERIA (COMPLETE AS OF 20-MAR-2020) * Prior invasive malignancy (except non-melanomatous skin cancer) unless disease free for a minimum of 1095 days (3 years); noninvasive cancers (for example, carcinoma in situ of the breast, oral cavity, or cervix are all permissible) are permitted even if diagnosed and treated \< 3 years ago * Patients with simultaneous primaries or bilateral tumors are excluded, with the exception of patients with bilateral tonsil cancers or patients with T1-2, N0, M0 resected differentiated thyroid carcinoma, who are eligible * Prior systemic chemotherapy or anti-epidermal growth factor (EGF) therapy for the study cancer; note that prior chemotherapy for a different cancer is allowable * Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields * Severe, active co-morbidity, defined as follows: * Unstable angina and/or congestive heart failure requiring hospitalization within 6 months prior to registration * Transmural myocardial infarction within 6 months prior to registration * Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration * Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of registration * Idiopathic pulmonary fibrosis or other severe interstitial lung disease that requires oxygen therapy or is thought to require oxygen therapy within 1 year prior to registration * Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects; note, however, that laboratory tests for coagulation parameters are not required for entry into this protocol * Acquired immune deficiency syndrome (AIDS) based upon current Centers for Disease and Control and Prevention (CDC) definition; note: human immunodeficiency virus (HIV) testing is not required for entry into this protocol; the need to exclude patients with AIDS from this protocol is necessary because the treatments involved in this protocol may be significantly immunosuppressive; protocol-specific requirements may also exclude immuno-compromised patients. * Grade 3-4 electrolyte abnormalities (Common Terminology Criteria for Adverse Events \[CTCAE\], version \[v.\] 4): * Serum calcium (ionized or adjusted for albumin) \< 7 mg/dl (1.75 mmol/L) or \> 12.5 mg/dl (\> 3.1 mmol/L) despite intervention to normalize levels * Glucose \< 40 mg/dl (\< 2.2 mmol/L) or \> 250 mg/dl (\> 14 mmol/L) * Magnesium \< 0.9 mg/dl (\< 0.4 mmol/L) or \> 3 mg/dl (\> 1.23 mmol/L) despite intervention to normalize levels * Potassium \< 3.0 mmol/L or \> 6 mmol/L despite intervention to normalize levels * Sodium \< 130 mmol/L or \> 155 mmol/L despite intervention to normalize levels * Pregnancy or women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraception; this exclusion is necessary because the treatment involved in this study may be significantly teratogenic * Prior allergic reaction to cetuximab * PHASE III: Prior invasive malignancy (except non-melanomatous skin cancer) unless disease free for a minimum of 1095 days (3 years) with the following exceptions: T1-2, N0, M0 resected differentiated thyroid carcinoma; Note that noninvasive cancers (For example, carcinoma in situ of the breast, oral cavity, or cervix) are permitted even if diagnosed and treated \< 3 years ago * PHASE III: Patients with simultaneous primaries or bilateral tumors are excluded, with the exception of patients with bilateral tonsil cancers or patients with T1-2, N0, M0 resected differentiated thyroid carcinoma, who are eligible * PHASE III: Prior systemic therapy, including cytotoxic chemotherapy, biologic/targeted therapy (such as anti-EGF therapy), or immune therapy for the study cancer; note that prior chemotherapy for a different cancer is allowable, however, a prior anti-PD-1, anti-PD-L1, or anti-PD-L2 agent is not permitted * PHASE III: Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields * PHASE III: Severe, active co-morbidity, defined as follows: * Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification; to be eligible for this trial, patients should be class 2B or better within 6 months prior to registration * Transmural myocardial infarction within 6 months prior to registration; * Severe infections within 4 weeks prior to registration including, but not limited to, hospitalization for complications of infection, bacteremia, or severe pneumonia; * Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration; Note: Patients receiving prophylactic antibiotics (e.g., for prevention of a urinary tract infection or chronic obstructive pulmonary disease exacerbation) are eligible. * Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of registration; * History of idiopathic pulmonary fibrosis, pneumonitis (including drug induced), organizing pneumonia (i.e., bronchiolitis obliterans, cryptogenic organizing pneumonia, etc.), or evidence of active pneumonitis on screening chest computed tomography (CT) scan. History of radiation pneumonitis in a prior radiation field (fibrosis) is permitted, provided that field does not overlap with the planned radiation field for the study cancer; * Patients with active tuberculosis (TB) are excluded; * Known clinically significant liver disease, including active viral, alcoholic, or other hepatitis; cirrhosis; fatty liver; and inherited liver disease; * Patients with past or resolved hepatitis B infection (defined as having a negative hepatitis B surface antigen \[HBsAg\] test and a positive anti-HBc \[antibody to hepatitis B core antigen\] antibody test) are eligible. * Patients positive for hepatitis C virus (HCV) antibody are eligible only if polymerase chain reaction (PCR) is negative for HCV RNA. * History of allogeneic bone marrow transplantation or solid organ transplantation. * A diagnosis of immunodeficiency: * Acquired immune deficiency syndrome (AIDS) based upon current CDC definition; note: HIV testing is not required for entry into this protocol; the need to exclude patients with AIDS from this protocol is necessary because the treatments involved in this protocol may be significantly immunosuppressive. * Is receiving treatment with systemic immunosuppressive medications (including, but not limited to, prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor \[anti-TNF\] agents) within 2 weeks prior to registration. * Note: Patients who have received acute, low dose, systemic immunosuppressant medications (e.g., a one-time dose of dexamethasone for nausea) may be enrolled. * Note: The use of inhaled corticosteroids and mineralocorticoids (e.g., fludrocortisone) for patients with orthostatic hypotension or adrenocortical insufficiency is allowed. * History or risk of autoimmune disease, including, but not limited to, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener's granulomatosis, Sjogren's syndrome, Guillain-Barré syndrome, multiple sclerosis, vasculitis, or glomerulonephritis. * Patients with a history of autoimmune hypothyroidism who are asymptomatic and/or are on a stable dose of thyroid replacement hormone are eligible. * Patients with controlled Type 1 diabetes mellitus on a stable insulin regimen are eligible. * Patients with eczema, psoriasis, lichen simplex chronicus, or vitiligo with dermatologic manifestations only (e.g., patients with psoriatic arthritis would be excluded) are permitted provided that they meet the following conditions: * Patients with psoriasis must have a baseline ophthalmologic exam to rule out ocular manifestations * Rash must cover less than 10% of body surface area (BSA) * Disease is well controlled at baseline and only requiring low potency topical steroids (e.g., hydrocortisone 2.5%, hydrocortisone butyrate 0.1%, flucinolone 0.01%, desonide 0.05%, aclometasone dipropionate 0.05%) * No acute exacerbations of underlying condition within the last 12 months (not requiring psoralen plus ultraviolet A radiation \[PUVA\], methotrexate, retinoids, biologic agents, oral calcineurin inhibitors; high potency or oral steroids) * PHASE III: Grade 3-4 electrolyte abnormalities (CTCAE, v. 4) within 14 days prior to registration: * Serum calcium (ionized or adjusted for albumin) \< 7 mg/dL (1.75 mmol/L) or \> 12.5 mg/dL (\> 3.1 mmol/L) despite intervention to normalize levels; * Glucose \< 40 mg/dL (\< 2.2 mmol/L) or \> 250 mg/dL (\> 14 mmol/L); * Magnesium \< 0.9 mg/dL (\< 0.4 mmol/L) or \> 3 mg/dL (\> 1.23 mmol/L) despite intervention to normalize levels; * Potassium \< 3.0 mmol/L or \> 6 mmol/L despite intervention to normalize levels; * Sodium \< 130 mmol/L or \> 155 mmol/L despite intervention to normalize levels. * PHASE III: Pregnancy or women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraception for up to 5 months from last study treatment; this exclusion is necessary because the treatment involved in this study may be significantly teratogenic. Women who are breastfeeding and unwilling to discontinue are also excluded * PHASE III: History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins * PHASE III: Patients taking bisphosphonate therapy for symptomatic hypercalcemia. Use of bisphosphonate therapy for other non-oncologic reasons (e.g., osteoporosis) is allowed * PHASE III: Patients requiring treatment with a RANKL inhibitor (e.g. denosumab) for non-oncologic reasons who cannot discontinue it before registration * PHASE III: Patients with known distant metastatic disease are excluded * PHASE III: Known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies * PHASE III: Major surgical procedure within 28 days prior to registration or anticipation of need for a major surgical procedure during the course of the study * PHASE III: Administration of a live, attenuated vaccine within 4 weeks prior to registration or anticipation that such a live, attenuated vaccine will be required during the study and for patients receiving atezolizumab, up to 5 months after the last dose of atezolizumab. * Influenza vaccination should be given during influenza season only (approximately October to

Study locations (338)

University of Alabama at Birmingham Cancer Center

Birmingham, Alabama, 35233

Active Not Recruiting

The Kirklin Clinic at Acton Road

Birmingham, Alabama, 35243

Suspended

Banner University Medical Center - Tucson

Tucson, Arizona, 85719

Recruiting
Site Public Contact · Contact
UACC-IIT@uacc.arizona.edu
Ricklie A. Julian · Principal Investigator

University of Arizona Cancer Center-North Campus

Tucson, Arizona, 85719

Recruiting
Site Public Contact · Contact
UACC-IIT@uacc.arizona.edu
Ricklie A. Julian · Principal Investigator

University of Arkansas for Medical Sciences

Little Rock, Arkansas, 72205

Active Not Recruiting

Sutter Cancer Centers Radiation Oncology Services-Auburn

Auburn, California, 95603

Recruiting
Site Public Contact · Contact
clinicalresearch@sutterhealth.org
Christopher U. Jones · Principal Investigator

Providence Saint Joseph Medical Center/Disney Family Cancer Center

Burbank, California, 91505

Recruiting
Site Public Contact · Contact
818-847-4793Najee.Boucher@providence.org
Dan S. Zuckerman · Principal Investigator

Sutter Cancer Centers Radiation Oncology Services-Cameron Park

Cameron Park, California, 95682

Recruiting
Site Public Contact · Contact
clinicalresearch@sutterhealth.org
Christopher U. Jones · Principal Investigator

Mercy San Juan Medical Center

Carmichael, California, 95608

Recruiting
Site Public Contact · Contact
720-874-1881ResearchInstituteInquiries@commonspirit.org
Shahzad Siddique · Principal Investigator

UC San Diego Health System - Encinitas

Encinitas, California, 92024

Suspended

UC San Diego Moores Cancer Center

La Jolla, California, 92093

Suspended

Cedars-Sinai Medical Center

Los Angeles, California, 90048

Recruiting
Site Public Contact · Contact
310-423-2133Cancer.trial.info@cshs.org
Zachary S. Zumsteg · Principal Investigator

Memorial Medical Center

Modesto, California, 95355

Recruiting
Site Public Contact · Contact
clinicalresearch@sutterhealth.org
Christopher U. Jones · Principal Investigator

UC Irvine Health/Chao Family Comprehensive Cancer Center

Orange, California, 92868

Active Not Recruiting

Stanford Cancer Institute Palo Alto

Palo Alto, California, 94304

Recruiting
Site Public Contact · Contact
650-498-7061ccto-office@stanford.edu
Michael Gensheimer · Principal Investigator

Sutter Cancer Centers Radiation Oncology Services-Roseville

Roseville, California, 95661

Recruiting
Site Public Contact · Contact
clinicalresearch@sutterhealth.org
Christopher U. Jones · Principal Investigator

Sutter Medical Center Sacramento

Sacramento, California, 95816

Recruiting
Site Public Contact · Contact
clinicalresearch@sutterhealth.org
Christopher U. Jones · Principal Investigator

University of California Davis Comprehensive Cancer Center

Sacramento, California, 95817

Suspended

UCSF Medical Center-Mount Zion

San Francisco, California, 94115

Suspended

UCSF Medical Center-Mission Bay

San Francisco, California, 94158

Suspended

Mills Health Center

San Mateo, California, 94401

Recruiting
Site Public Contact · Contact
clinicalresearch@sutterhealth.org
Christopher U. Jones · Principal Investigator

Saint Helena Hospital

St. Helena, California, 94574

Active Not Recruiting

UCHealth University of Colorado Hospital

Aurora, Colorado, 80045

Active Not Recruiting

Rocky Mountain Cancer Centers-Boulder

Boulder, Colorado, 80304

Active Not Recruiting

Penrose-Saint Francis Healthcare

Colorado Springs, Colorado, 80907

Recruiting
Site Public Contact · Contact
720-874-1881ResearchInstituteInquiries@CommonSpirit.org
Shahzad Siddique · Principal Investigator

AdventHealth Porter

Denver, Colorado, 80210

Recruiting
Site Public Contact · Contact
research.institute@adventhealth.com
Nadine G. Mikhaeel-Kamel · Principal Investigator

Shaw Cancer Center

Edwards, Colorado, 81632

Recruiting
Site Public Contact · Contact
970-569-7429
Patricia H. Hardenbergh · Principal Investigator

Banner North Colorado Medical Center

Greeley, Colorado, 80631

Suspended

Rocky Mountain Cancer Centers-Littleton

Littleton, Colorado, 80120

Active Not Recruiting

Longmont United Hospital

Longmont, Colorado, 80501

Recruiting
Site Public Contact · Contact
720-874-1881ResearchInstituteInquiries@CommonSpirit.org
Shahzad Siddique · Principal Investigator

Banner North Colorado Medical Center - Loveland Campus

Loveland, Colorado, 80539

Suspended

AdventHealth Parker

Parker, Colorado, 80138

Recruiting
Site Public Contact · Contact
research.institute@adventhealth.com
Nadine G. Mikhaeel-Kamel · Principal Investigator

University of Connecticut

Farmington, Connecticut, 06030

Active Not Recruiting

Yale University

New Haven, Connecticut, 06520

Recruiting
Site Public Contact · Contact
203-785-5702canceranswers@yale.edu
Melissa R. Young · Principal Investigator

Smilow Cancer Hospital Care Center - Waterford

Waterford, Connecticut, 06385

Recruiting
Site Public Contact · Contact
203-785-5702canceranswers@yale.edu
Melissa R. Young · Principal Investigator

Helen F Graham Cancer Center

Newark, Delaware, 19713

Suspended

Christiana Care Health System-Christiana Hospital

Newark, Delaware, 19718

Suspended

George Washington University Medical Center

Washington D.C., District of Columbia, 20037

Recruiting
Site Public Contact · Contact
202-741-2210
Julie E. Bauman · Principal Investigator

UM Sylvester Comprehensive Cancer Center at Deerfield Beach

Deerfield Beach, Florida, 33442

Active Not Recruiting

Holy Cross Hospital

Fort Lauderdale, Florida, 33308

Recruiting
Site Public Contact · Contact
eileen.georgi@holy-cross.com
Samir Narayan · Principal Investigator

University of Miami Miller School of Medicine-Sylvester Cancer Center

Miami, Florida, 33136

Active Not Recruiting

AdventHealth Orlando

Orlando, Florida, 32803

Active Not Recruiting

Orlando Health Cancer Institute

Orlando, Florida, 32806

Recruiting
Site Public Contact · Contact
321-841-7246CancerClinicalTrials@orlandohealth.com
Rafael R. Manon · Principal Investigator

Moffitt Cancer Center at SouthShore

Ruskin, Florida, 33570

Recruiting
Site Public Contact · Contact
800-679-0775ClinicalTrials@moffitt.org
Jimmy J. Caudell · Principal Investigator

Moffitt Cancer Center-International Plaza

Tampa, Florida, 33607

Recruiting
Site Public Contact · Contact
800-679-0775ClinicalTrials@moffitt.org
Jimmy J. Caudell · Principal Investigator

Moffitt Cancer Center

Tampa, Florida, 33612

Recruiting
Site Public Contact · Contact
800-679-0775ClinicalTrials@moffitt.org
Jimmy J. Caudell · Principal Investigator

Emory University Hospital Midtown

Atlanta, Georgia, 30308

Recruiting
Site Public Contact · Contact
888-946-7447
James E. Bates · Principal Investigator

Emory University Hospital/Winship Cancer Institute

Atlanta, Georgia, 30322

Recruiting
Site Public Contact · Contact
404-778-1868
James E. Bates · Principal Investigator

Augusta University Medical Center

Augusta, Georgia, 30912

Suspended

Memorial Health University Medical Center

Savannah, Georgia, 31404

Recruiting
Site Public Contact · Contact
912-350-7887Lorraine.OHara@hcahealthcare.com
Aaron W. Pederson · Principal Investigator

Lewis Cancer and Research Pavilion at Saint Joseph's/Candler

Savannah, Georgia, 31405

Active Not Recruiting

Queen's Medical Center

Honolulu, Hawaii, 96813

Active Not Recruiting

The Cancer Center of Hawaii-Liliha

Honolulu, Hawaii, 96817

Active Not Recruiting

Saint Alphonsus Cancer Care Center-Nampa

Nampa, Idaho, 83687

Recruiting
Site Public Contact · Contact
406-969-6060mccinfo@mtcancer.org
Samir Narayan · Principal Investigator

Northwestern University

Chicago, Illinois, 60611

Suspended

John H Stroger Jr Hospital of Cook County

Chicago, Illinois, 60612

Recruiting
Site Public Contact · Contact
312-864-5204
Deimante M. Tamkus · Principal Investigator

Rush MD Anderson Cancer Center

Chicago, Illinois, 60612

Active Not Recruiting

University of Illinois

Chicago, Illinois, 60612

Active Not Recruiting

Decatur Memorial Hospital

Decatur, Illinois, 62526

Recruiting
Site Public Contact · Contact
217-876-4762morganthaler.jodi@mhsil.com
Bryan A. Faller · Principal Investigator

Crossroads Cancer Center

Effingham, Illinois, 62401

Recruiting
Site Public Contact · Contact
217-876-4762morganthaler.jodi@mhsil.com
Bryan A. Faller · Principal Investigator

NorthShore University HealthSystem-Evanston Hospital

Evanston, Illinois, 60201

Recruiting
Site Public Contact · Contact
847-570-2109
Bruce E. Brockstein · Principal Investigator

NorthShore University HealthSystem-Glenbrook Hospital

Glenview, Illinois, 60026

Recruiting
Site Public Contact · Contact
847-570-2109
Bruce E. Brockstein · Principal Investigator

NorthShore University HealthSystem-Highland Park Hospital

Highland Park, Illinois, 60035

Recruiting
Site Public Contact · Contact
847-570-2109
Bruce E. Brockstein · Principal Investigator

HSHS Saint Elizabeth's Hospital

O'Fallon, Illinois, 62269

Recruiting
Site Public Contact · Contact
217-876-4762morganthaler.jodi@mhsil.com
Bryan A. Faller · Principal Investigator

Advocate Christ Medical Center

Oak Lawn, Illinois, 60453-2699

Active Not Recruiting

OSF Saint Francis Radiation Oncology at Peoria Cancer Center

Peoria, Illinois, 61615

Recruiting
Site Public Contact · Contact
309-243-3605andersonj@illinoiscancercare.com
Bryan A. Faller · Principal Investigator

OSF Saint Francis Medical Center

Peoria, Illinois, 61637

Recruiting
Site Public Contact · Contact
309-243-3605andersonj@illinoiscancercare.com
Bryan A. Faller · Principal Investigator

UW Health Carbone Cancer Center Rockford

Rockford, Illinois, 61114

Recruiting
Site Public Contact · Contact
779-696-9378lkline@uwhealth.org
Fahrettin Covut · Principal Investigator

Springfield Memorial Hospital

Springfield, Illinois, 62781

Recruiting
Site Public Contact · Contact
217-528-7541pallante.beth@mhsil.com
Bryan A. Faller · Principal Investigator

Carle Cancer Center

Urbana, Illinois, 61801

Recruiting
Site Public Contact · Contact
800-446-5532Research@carle.com
Sinisa Stanic · Principal Investigator

Ascension Saint Vincent Anderson

Anderson, Indiana, 46016

Active Not Recruiting

Elkhart General Hospital

Elkhart, Indiana, 46515

Active Not Recruiting

Radiation Oncology Associates PC

Fort Wayne, Indiana, 46804

Suspended

Parkview Hospital Randallia

Fort Wayne, Indiana, 46805

Active Not Recruiting

Parkview Regional Medical Center

Fort Wayne, Indiana, 46845

Active Not Recruiting

Goshen Center for Cancer Care

Goshen, Indiana, 46526

Active Not Recruiting

Indiana University/Melvin and Bren Simon Cancer Center

Indianapolis, Indiana, 46202

Suspended

IU Health Methodist Hospital

Indianapolis, Indiana, 46202

Suspended

IU Health Central Indiana Cancer Centers-East

Indianapolis, Indiana, 46219

Active Not Recruiting

Michiana Hematology Oncology PC-Mishawaka

Mishawaka, Indiana, 46545

Active Not Recruiting

Memorial Hospital of South Bend

South Bend, Indiana, 46601

Active Not Recruiting

McFarland Clinic - Ames

Ames, Iowa, 50010

Active Not Recruiting

Iowa Methodist Medical Center

Des Moines, Iowa, 50309

Active Not Recruiting

University of Kansas Cancer Center

Kansas City, Kansas, 66160

Recruiting
Site Public Contact · Contact
913-588-3671KUCC_Navigation@kumc.edu
Christopher Lominska · Principal Investigator

Lawrence Memorial Hospital

Lawrence, Kansas, 66044

Recruiting
Site Public Contact · Contact
785-505-2800Stephanie.Norris@LMH.ORG
Christopher Lominska · Principal Investigator

The University of Kansas Cancer Center - Olathe

Olathe, Kansas, 66061

Recruiting
Site Public Contact · Contact
913-588-1569OlatheCCResearch@kumc.edu
Christopher Lominska · Principal Investigator

University of Kansas Cancer Center-Overland Park

Overland Park, Kansas, 66210

Recruiting
Site Public Contact · Contact
913-588-3671KUCC_Navigation@kumc.edu
Christopher Lominska · Principal Investigator

Salina Regional Health Center

Salina, Kansas, 67401

Recruiting
Site Public Contact · Contact
785-452-7038mleepers@srhc.com
Christopher Lominska · Principal Investigator

University of Kentucky/Markey Cancer Center

Lexington, Kentucky, 40536

Active Not Recruiting

The James Graham Brown Cancer Center at University of Louisville

Louisville, Kentucky, 40202

Recruiting
Site Public Contact · Contact
502-562-3429
Neal E. Dunlap · Principal Investigator

UofL Health Medical Center Northeast

Louisville, Kentucky, 40245

Recruiting
Site Public Contact · Contact
502-852-2755ctoinfo@louisville.edu
Neal E. Dunlap · Principal Investigator

LSU Health Baton Rouge-North Clinic

Baton Rouge, Louisiana, 70805

Recruiting
Site Public Contact · Contact
225-765-7659research@ololrmc.com
Marshall P. Stagg · Principal Investigator

Our Lady of the Lake Physician Group

Baton Rouge, Louisiana, 70808

Recruiting
Site Public Contact · Contact
225-765-7659research@ololrmc.com
Marshall P. Stagg · Principal Investigator

Our Lady of The Lake

Baton Rouge, Louisiana, 70808

Suspended

Tulane University School of Medicine

New Orleans, Louisiana, 70112

Active Not Recruiting

University Medical Center New Orleans

New Orleans, Louisiana, 70112

Recruiting
Site Public Contact · Contact
504-210-3539emede1@lsuhsc.edu
Brian C. Boulmay · Principal Investigator

Touro Infirmary

New Orleans, Louisiana, 70115

Recruiting
Site Public Contact · Contact
504-210-3539emede1@lsuhsc.edu
Brian C. Boulmay · Principal Investigator

Ochsner Medical Center Jefferson

New Orleans, Louisiana, 70121

Active Not Recruiting

University of Maryland/Greenebaum Cancer Center

Baltimore, Maryland, 21201

Recruiting
Site Public Contact · Contact
800-888-8823
Matthew J. Ferris · Principal Investigator

Greater Baltimore Medical Center

Baltimore, Maryland, 21204

Recruiting
Site Public Contact · Contact
443-849-3706
Mei Tang · Principal Investigator

Johns Hopkins University/Sidney Kimmel Cancer Center

Baltimore, Maryland, 21287

Recruiting
Site Public Contact · Contact
410-955-8804jhcccro@jhmi.edu
Ana P. Kiess · Principal Investigator

UM Upper Chesapeake Medical Center

Bel Air, Maryland, 21014

Recruiting
Site Public Contact · Contact
443-643-3010
Kamila Nowak Choi · Principal Investigator

Central Maryland Radiation Oncology in Howard County

Columbia, Maryland, 21044

Recruiting
Site Public Contact · Contact
443-546-1300
Matthew J. Ferris · Principal Investigator

UM Baltimore Washington Medical Center/Tate Cancer Center

Glen Burnie, Maryland, 21061

Recruiting
Site Public Contact · Contact
410-553-8100
Matthew J. Ferris · Principal Investigator

Holy Cross Hospital

Silver Spring, Maryland, 20910

Active Not Recruiting

Boston Medical Center

Boston, Massachusetts, 02118

Recruiting
Site Public Contact · Contact
617-638-8265
Minh T. Truong · Principal Investigator

Trinity Health Saint Joseph Mercy Hospital Ann Arbor

Ann Arbor, Michigan, 48106

Recruiting
Site Public Contact · Contact
734-712-7251MCRCwebsitecontactform@stjoeshealth.org
Samir Narayan · Principal Investigator

University of Michigan Rogel Cancer Center

Ann Arbor, Michigan, 48109

Active Not Recruiting

Trinity Health Medical Center - Brighton

Brighton, Michigan, 48114

Recruiting
Site Public Contact · Contact
734-712-7251MCRCwebsitecontactform@stjoeshealth.org
Samir Narayan · Principal Investigator

University of Michigan - Brighton Center for Specialty Care

Brighton, Michigan, 48116

Active Not Recruiting

Henry Ford Cancer Institute-Downriver

Brownstown, Michigan, 48183

Recruiting
Site Public Contact · Contact
313-916-3721CTOResearch@hfhs.org
Eleanor M. Walker · Principal Investigator

Henry Ford Macomb Hospital-Clinton Township

Clinton Township, Michigan, 48038

Recruiting
Site Public Contact · Contact
313-916-3721CTOResearch@hfhs.org
Eleanor M. Walker · Principal Investigator

Henry Ford Medical Center-Fairlane

Dearborn, Michigan, 48126

Recruiting
Site Public Contact · Contact
313-916-3721CTOResearch@hfhs.org
Eleanor M. Walker · Principal Investigator

Henry Ford Hospital

Detroit, Michigan, 48202

Recruiting
Site Public Contact · Contact
313-916-3721CTOResearch@hfhs.org
Eleanor M. Walker · Principal Investigator

Corewell Health Grand Rapids Hospitals - Butterworth Hospital

Grand Rapids, Michigan, 49503

Recruiting
Site Public Contact · Contact
616-391-1230crcwm-regulatory@crcwm.org
Kathleen Y. Butler · Principal Investigator

Allegiance Health

Jackson, Michigan, 49201

Recruiting
Site Public Contact · Contact
313-916-3721CTOResearch@hfhs.org
Eleanor M. Walker · Principal Investigator

West Michigan Cancer Center

Kalamazoo, Michigan, 49007

Recruiting
Site Public Contact · Contact
616-391-1230crcwm-regulatory@crcwm.org
Kathleen Y. Butler · Principal Investigator

University of Michigan Health - Sparrow Lansing

Lansing, Michigan, 48912

Recruiting
Site Public Contact · Contact
517-364-3712harsha.trivedi@umhsparrow.org
Samir Narayan · Principal Investigator

Trinity Health Saint Mary Mercy Livonia Hospital

Livonia, Michigan, 48154

Recruiting
Site Public Contact · Contact
734-712-7251MCRCwebsitecontactform@stjoeshealth.org
Samir Narayan · Principal Investigator

Henry Ford Medical Center-Columbus

Novi, Michigan, 48377

Recruiting
Site Public Contact · Contact
313-916-3721CTOResearch@hfhs.org
Eleanor M. Walker · Principal Investigator

Corewell Health William Beaumont University Hospital

Royal Oak, Michigan, 48073

Active Not Recruiting

MyMichigan Medical Center Saginaw

Saginaw, Michigan, 48601

Recruiting
Site Public Contact · Contact
734-712-7251MCRCwebsitecontactform@stjoeshealth.org
Samir Narayan · Principal Investigator

Corewell Health Beaumont Troy Hospital

Troy, Michigan, 48085

Active Not Recruiting

Henry Ford West Bloomfield Hospital

West Bloomfield, Michigan, 48322

Recruiting
Site Public Contact · Contact
313-916-3721CTOResearch@hfhs.org
Eleanor M. Walker · Principal Investigator

Henry Ford Wyandotte Hospital

Wyandotte, Michigan, 48192

Recruiting
Site Public Contact · Contact
nhay@hfhs.org
Eleanor M. Walker · Principal Investigator

University of Michigan Health - West

Wyoming, Michigan, 49519

Recruiting
Site Public Contact · Contact
616-391-1230crcwm-regulatory@crcwm.org
Kathleen Y. Butler · Principal Investigator

Sanford Joe Lueken Cancer Center

Bemidji, Minnesota, 56601

Recruiting
Site Public Contact · Contact
218-333-5000OncologyClinicalTrialsFargo@sanfordhealth.org
Daniel Almquist · Principal Investigator

Minnesota Oncology - Burnsville

Burnsville, Minnesota, 55337

Recruiting
Site Public Contact · Contact
952-993-1517mmcorc@healthpartners.com
Charles Shideman · Principal Investigator

Miller-Dwan Hospital

Duluth, Minnesota, 55805

Recruiting
Site Public Contact · Contact
218-786-3308CancerTrials@EssentiaHealth.org
Bret E. Friday · Principal Investigator

Hennepin County Medical Center

Minneapolis, Minnesota, 55415

Recruiting
Site Public Contact · Contact
952-993-1517mmcorc@healthpartners.com
Charles Shideman · Principal Investigator

North Memorial Medical Health Center

Robbinsdale, Minnesota, 55422

Recruiting
Site Public Contact · Contact
952-993-1517mmcorc@healthpartners.com
Charles Shideman · Principal Investigator

Mayo Clinic in Rochester

Rochester, Minnesota, 55905

Recruiting
Site Public Contact · Contact
855-776-0015
Katharine A. Price · Principal Investigator

Coborn Cancer Center at Saint Cloud Hospital

Saint Cloud, Minnesota, 56303

Recruiting
Site Public Contact · Contact
877-229-4907coborncancercenter@centracare.com
Donald J. Jurgens · Principal Investigator

University of Mississippi Medical Center

Jackson, Mississippi, 39216

Suspended

Saint Francis Medical Center

Cape Girardeau, Missouri, 63703

Recruiting
Site Public Contact · Contact
573-334-2230sfmc@sfmc.net
Bryan A. Faller · Principal Investigator

Siteman Cancer Center at Saint Peters Hospital

City of Saint Peters, Missouri, 63376

Recruiting
Site Public Contact · Contact
800-600-3606info@siteman.wustl.edu
Wade L. Thorstad · Principal Investigator

MU Health - University Hospital/Ellis Fischel Cancer Center

Columbia, Missouri, 65212

Active Not Recruiting

Siteman Cancer Center at West County Hospital

Creve Coeur, Missouri, 63141

Recruiting
Site Public Contact · Contact
800-600-3606info@siteman.wustl.edu
Wade L. Thorstad · Principal Investigator

North Kansas City Hospital

Kansas City, Missouri, 64116

Suspended

The University of Kansas Cancer Center-South

Kansas City, Missouri, 64131

Suspended

University of Kansas Cancer Center - North

Kansas City, Missouri, 64154

Recruiting
Site Public Contact · Contact
913-588-3671KUCC_Navigation@kumc.edu
Christopher Lominska · Principal Investigator

University of Kansas Cancer Center - Lee's Summit

Lee's Summit, Missouri, 64064

Recruiting
Site Public Contact · Contact
913-588-3671KUCC_Navigation@kumc.edu
Christopher Lominska · Principal Investigator

Phelps Health Delbert Day Cancer Institute

Rolla, Missouri, 65401

Recruiting
Site Public Contact · Contact
573-458-7504research@phelpshealth.org
Jay W. Carlson · Principal Investigator

Mercy Hospital Springfield

Springfield, Missouri, 65804

Recruiting
Site Public Contact · Contact
417-269-4520
Jay W. Carlson · Principal Investigator

CoxHealth South Hospital

Springfield, Missouri, 65807

Recruiting
Site Public Contact · Contact
417-269-4520
Jay W. Carlson · Principal Investigator

Washington University School of Medicine

St Louis, Missouri, 63110

Recruiting
Site Public Contact · Contact
800-600-3606info@siteman.wustl.edu
Wade L. Thorstad · Principal Investigator

Siteman Cancer Center-South County

St Louis, Missouri, 63129

Active Not Recruiting

Missouri Baptist Medical Center

St Louis, Missouri, 63131

Recruiting
Site Public Contact · Contact
314-996-5569
Bryan A. Faller · Principal Investigator

Mercy Hospital Saint Louis

St Louis, Missouri, 63141

Recruiting
Site Public Contact · Contact
314-251-7066
Jay W. Carlson · Principal Investigator

CHI Health Good Samaritan

Kearney, Nebraska, 68847

Recruiting
Site Public Contact · Contact
720-874-1881ResearchInstituteInquiries@CommonSpirit.org
Shahzad Siddique · Principal Investigator

Nebraska Methodist Hospital

Omaha, Nebraska, 68114

Active Not Recruiting

Alegent Health Bergan Mercy Medical Center

Omaha, Nebraska, 68124

Recruiting
Site Public Contact · Contact
720-874-1881ResearchInstituteInquiries@CommonSpirit.org
Shahzad Siddique · Principal Investigator

Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center

Lebanon, New Hampshire, 03756

Recruiting
Site Public Contact · Contact
800-639-6918cancer.research.nurse@dartmouth.edu
Garrett T. Wasp · Principal Investigator

Memorial Sloan Kettering Basking Ridge

Basking Ridge, New Jersey, 07920

Recruiting
Site Public Contact · Contact
212-639-7592
Nancy Y. Lee · Principal Investigator

The Cancer Institute of New Jersey Hamilton

Hamilton, New Jersey, 08690

Recruiting
Site Public Contact · Contact
609-631-6946
Dylan F. Roden · Principal Investigator

Saint Barnabas Medical Center

Livingston, New Jersey, 07039

Recruiting
Site Public Contact · Contact
973-322-2934joanne.loeb@rwjbh.org
Dylan F. Roden · Principal Investigator

Monmouth Medical Center

Long Branch, New Jersey, 07740

Recruiting
Site Public Contact · Contact
732-923-6564mary.danish@rwjbh.org
Dylan F. Roden · Principal Investigator

Memorial Sloan Kettering Monmouth

Middletown, New Jersey, 07748

Recruiting
Site Public Contact · Contact
212-639-7592
Nancy Y. Lee · Principal Investigator

Memorial Sloan Kettering Bergen

Montvale, New Jersey, 07645

Recruiting
Site Public Contact · Contact
212-639-7592
Nancy Y. Lee · Principal Investigator

Virtua Memorial

Mount Holly, New Jersey, 08060

Active Not Recruiting

Rutgers Cancer Institute of New Jersey

New Brunswick, New Jersey, 08903

Recruiting
Site Public Contact · Contact
732-235-7356
Dylan F. Roden · Principal Investigator

Rutgers New Jersey Medical School

Newark, New Jersey, 07101

Recruiting
Site Public Contact · Contact
732-235-7356
Dylan F. Roden · Principal Investigator

Robert Wood Johnson University Hospital Somerset

Somerville, New Jersey, 08876

Recruiting
Site Public Contact · Contact
908-685-2481Siby.Varughese@rwjbh.org
Dylan F. Roden · Principal Investigator

Sparta Cancer Treatment Center

Sparta, New Jersey, 07871

Suspended

Community Medical Center

Toms River, New Jersey, 08755

Recruiting
Site Public Contact · Contact
732-557-8294Lennette.Gonzales@rwjbh.org
Dylan F. Roden · Principal Investigator

Virtua Voorhees

Voorhees Township, New Jersey, 08043

Active Not Recruiting

University of New Mexico Cancer Center

Albuquerque, New Mexico, 87106

Recruiting
Site Public Contact · Contact
505-925-0348HSC-ClinicalTrialInfo@salud.unm.edu
Thomas M. Schroeder · Principal Investigator

New Mexico Oncology Hematology Consultants

Albuquerque, New Mexico, 87109

Recruiting
Site Public Contact · Contact
505-272-0530CLee@nmcca.org
Thomas M. Schroeder · Principal Investigator

South Shore University Hospital

Bay Shore, New York, 11706

Active Not Recruiting

New York-Presbyterian/Brooklyn Methodist Hospital

Brooklyn, New York, 11215

Suspended

NYU Langone Hospital - Brooklyn

Brooklyn, New York, 11220

Active Not Recruiting

Roswell Park Cancer Institute

Buffalo, New York, 14263

Active Not Recruiting

Sands Cancer Center

Canandaigua, New York, 14424

Recruiting
Site Public Contact · Contact
585-396-6161
Yuhchyau Chen · Principal Investigator

Memorial Sloan Kettering Commack

Commack, New York, 11725

Recruiting
Site Public Contact · Contact
212-639-7592
Nancy Y. Lee · Principal Investigator

Arnot Ogden Medical Center/Falck Cancer Center

Elmira, New York, 14905

Suspended

Memorial Sloan Kettering Westchester

Harrison, New York, 10604

Recruiting
Site Public Contact · Contact
212-639-7592
Nancy Y. Lee · Principal Investigator

Northwell Health/Center for Advanced Medicine

Lake Success, New York, 11042

Active Not Recruiting

NYU Langone Hospital - Long Island

Mineola, New York, 11501

Recruiting
Site Public Contact · Contact
212-263-4432cancertrials@nyulangone.org
Kenneth S. Hu · Principal Investigator

Mount Sinai Union Square

New York, New York, 10003

Recruiting
Site Public Contact · Contact
212-824-7309CCTO@mssm.edu
Karyn A. Goodman · Principal Investigator

Laura and Isaac Perlmutter Cancer Center at NYU Langone

New York, New York, 10016

Recruiting
Site Public Contact · Contact
CancerTrials@nyulangone.org
Kenneth S. Hu · Principal Investigator

NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center

New York, New York, 10032

Active Not Recruiting

Memorial Sloan Kettering Cancer Center

New York, New York, 10065

Recruiting
Site Public Contact · Contact
212-639-7592
Nancy Y. Lee · Principal Investigator

Wilmot Cancer Institute Radiation Oncology at Greece

Rochester, New York, 14606

Recruiting
Site Public Contact · Contact
585-758-7877
Yuhchyau Chen · Principal Investigator

Highland Hospital

Rochester, New York, 14620

Recruiting
Site Public Contact · Contact
585-341-8113
Yuhchyau Chen · Principal Investigator

University of Rochester

Rochester, New York, 14642

Recruiting
Site Public Contact · Contact
585-275-5830
Yuhchyau Chen · Principal Investigator

Memorial Sloan Kettering Sleepy Hollow

Sleepy Hollow, New York, 10591

Active Not Recruiting

State University of New York Upstate Medical University

Syracuse, New York, 13210

Recruiting
Site Public Contact · Contact
315-464-5476
Hsin K. Li · Principal Investigator

Montefiore Medical Center-Einstein Campus

The Bronx, New York, 10461

Recruiting
Site Public Contact · Contact
718-379-6866eskwak@montefiore.org
Rafi Kabarriti · Principal Investigator

Montefiore Medical Center - Moses Campus

The Bronx, New York, 10467

Recruiting
Site Public Contact · Contact
718-379-6866eskwak@montefiore.org
Rafi Kabarriti · Principal Investigator

Memorial Sloan Kettering Nassau

Uniondale, New York, 11553

Recruiting
Site Public Contact · Contact
212-639-7592
Nancy Y. Lee · Principal Investigator

Atrium Health Stanly/LCI-Albemarle

Albemarle, North Carolina, 28002

Recruiting
Site Public Contact · Contact
800-804-9376
Benjamin J. Moeller · Principal Investigator

UNC Lineberger Comprehensive Cancer Center

Chapel Hill, North Carolina, 27599

Recruiting
Site Public Contact · Contact
877-668-0683cancerclinicaltrials@med.unc.edu
Sumita Trivedi · Principal Investigator

Carolinas Medical Center/Levine Cancer Institute

Charlotte, North Carolina, 28203

Recruiting
Site Public Contact · Contact
800-804-9376
Benjamin J. Moeller · Principal Investigator

Atrium Health Pineville/LCI-Pineville

Charlotte, North Carolina, 28210

Recruiting
Site Public Contact · Contact
980-442-2000
Benjamin J. Moeller · Principal Investigator

Atrium Health University City/LCI-University

Charlotte, North Carolina, 28262

Recruiting
Site Public Contact · Contact
800-804-9376
Benjamin J. Moeller · Principal Investigator

Atrium Health Cabarrus/LCI-Concord

Concord, North Carolina, 28025

Recruiting
Site Public Contact · Contact
800-804-9376
Benjamin J. Moeller · Principal Investigator

East Carolina University

Greenville, North Carolina, 27834

Suspended

ECU Health Oncology Kinston

Kinston, North Carolina, 28501

Recruiting
Site Public Contact · Contact
252-559-2201research@ecuhealth.org
Misbah U. Qadir · Principal Investigator

Atrium Health Union/LCI-Union

Monroe, North Carolina, 28112

Recruiting
Site Public Contact · Contact
980-442-2000
Benjamin J. Moeller · Principal Investigator

Wake Forest University Health Sciences

Winston-Salem, North Carolina, 27157

Active Not Recruiting

Sanford Bismarck Medical Center

Bismarck, North Dakota, 58501

Recruiting
Site Public Contact · Contact
701-323-5760OncologyClinicalTrialsFargo@sanfordhealth.org
Daniel Almquist · Principal Investigator

Sanford Roger Maris Cancer Center

Fargo, North Dakota, 58122

Recruiting
Site Public Contact · Contact
701-234-6161OncologyClinicalTrialsFargo@sanfordhealth.org
Daniel Almquist · Principal Investigator

Summa Health System - Akron Campus

Akron, Ohio, 44304

Active Not Recruiting

Cleveland Clinic Akron General

Akron, Ohio, 44307

Active Not Recruiting

UH Seidman Cancer Center at UH Avon Health Center

Avon, Ohio, 44011

Recruiting
Site Public Contact · Contact
800-641-2422
Jennifer A. Dorth · Principal Investigator

Summa Health System - Barberton Campus

Barberton, Ohio, 44203

Active Not Recruiting

UHHS-Chagrin Highlands Medical Center

Beachwood, Ohio, 44122

Recruiting
Site Public Contact · Contact
800-641-2422CTUReferral@UHhospitals.org
Jennifer A. Dorth · Principal Investigator

Geauga Hospital

Chardon, Ohio, 44024

Recruiting
Site Public Contact · Contact
800-641-2422CTUReferral@UHhospitals.org
Jennifer A. Dorth · Principal Investigator

Adena Regional Medical Center

Chillicothe, Ohio, 45601

Recruiting
Site Public Contact · Contact
877-779-7585Jeffh@columbusccop.org
Aruna C. Gowda · Principal Investigator

University of Cincinnati Cancer Center-UC Medical Center

Cincinnati, Ohio, 45219

Suspended

Case Western Reserve University

Cleveland, Ohio, 44106

Recruiting
Site Public Contact · Contact
800-641-2422CTUReferral@UHhospitals.org
Jennifer A. Dorth · Principal Investigator

MetroHealth Medical Center

Cleveland, Ohio, 44109

Active Not Recruiting

Cleveland Clinic Cancer Center/Fairview Hospital

Cleveland, Ohio, 44111

Active Not Recruiting

Cleveland Clinic Foundation

Cleveland, Ohio, 44195

Recruiting
Site Public Contact · Contact
866-223-8100TaussigResearch@ccf.org
Jessica L. Geiger · Principal Investigator

Ohio State University Comprehensive Cancer Center

Columbus, Ohio, 43210

Recruiting
Site Public Contact · Contact
800-293-5066Jamesline@osumc.edu
Dukagjin M. Blakaj · Principal Investigator

Mercy Cancer Center-Elyria

Elyria, Ohio, 44035

Suspended

Cleveland Clinic Cancer Center Independence

Independence, Ohio, 44131

Suspended

OhioHealth Mansfield Hospital

Mansfield, Ohio, 44903

Suspended

Hillcrest Hospital Cancer Center

Mayfield Heights, Ohio, 44124

Active Not Recruiting

Summa Health Medina Medical Center

Medina, Ohio, 44256

Active Not Recruiting

UH Seidman Cancer Center at Lake Health Mentor Campus

Mentor, Ohio, 44060

Recruiting
Site Public Contact · Contact
800-641-2422CTUReferral@UHhospitals.org
Jennifer A. Dorth · Principal Investigator

UH Seidman Cancer Center at Southwest General Hospital

Middleburg Heights, Ohio, 44130

Recruiting
Site Public Contact · Contact
800-641-2422CTUReferral@UHhospitals.org
Jennifer A. Dorth · Principal Investigator

University Hospitals Parma Medical Center

Parma, Ohio, 44129

Recruiting
Site Public Contact · Contact
800-641-2422CTUReferral@UHhospitals.org
Jennifer A. Dorth · Principal Investigator

Southern Ohio Medical Center

Portsmouth, Ohio, 45662

Recruiting
Site Public Contact · Contact
614-488-2745Jeffh@columbusccop.org
Aruna C. Gowda · Principal Investigator

University Hospitals Portage Medical Center

Ravenna, Ohio, 44266

Recruiting
Site Public Contact · Contact
800-641-2422CTUReferral@UHhospitals.org
Jennifer A. Dorth · Principal Investigator

North Coast Cancer Care

Sandusky, Ohio, 44870

Active Not Recruiting

UH Seidman Cancer Center at Firelands Regional Medical Center

Sandusky, Ohio, 44870

Recruiting
Site Public Contact · Contact
800-641-2422CTUReferral@UHhospitals.org
Jennifer A. Dorth · Principal Investigator

Cleveland Clinic Cancer Center Strongsville

Strongsville, Ohio, 44136

Recruiting
Site Public Contact · Contact
866-223-8100TaussigResearch@ccf.org
Jessica L. Geiger · Principal Investigator

University of Cincinnati Cancer Center-West Chester

West Chester, Ohio, 45069

Suspended

UHHS-Westlake Medical Center

Westlake, Ohio, 44145

Recruiting
Site Public Contact · Contact
800-641-2422CTUReferral@UHhospitals.org
Jennifer A. Dorth · Principal Investigator

Cleveland Clinic Wooster Family Health and Surgery Center

Wooster, Ohio, 44691

Recruiting
Site Public Contact · Contact
866-223-8100TaussigResearch@ccf.org
Jessica L. Geiger · Principal Investigator

University of Oklahoma Health Sciences Center

Oklahoma City, Oklahoma, 73104

Recruiting
Site Public Contact · Contact
405-271-8777ou-clinical-trials@ouhsc.edu
Christina Henson · Principal Investigator

Clackamas Radiation Oncology Center

Clackamas, Oregon, 97015

Recruiting
Site Public Contact · Contact
503-215-2614CanRsrchStudies@providence.org
Dan S. Zuckerman · Principal Investigator

Providence Portland Medical Center

Portland, Oregon, 97213

Recruiting
Site Public Contact · Contact
503-215-2614CanRsrchStudies@providence.org
Dan S. Zuckerman · Principal Investigator

Providence Saint Vincent Medical Center

Portland, Oregon, 97225

Recruiting
Site Public Contact · Contact
503-215-2614CanRsrchStudies@providence.org
Dan S. Zuckerman · Principal Investigator

Lehigh Valley Hospital-Cedar Crest

Allentown, Pennsylvania, 18103

Recruiting
Site Public Contact · Contact
610-402-9543Morgan_M.Horton@lvhn.org
Samir Narayan · Principal Investigator

Saint Luke's Cancer Center - Allentown

Allentown, Pennsylvania, 18104

Recruiting
Site Public Contact · Contact
610-776-4714
Diane M. Hershock · Principal Investigator

UPMC Altoona

Altoona, Pennsylvania, 16601

Recruiting
Site Public Contact · Contact
412-339-5294Roster@nrgoncology.org
Heath D. Skinner · Principal Investigator

UPMC-Heritage Valley Health System Beaver

Beaver, Pennsylvania, 15009

Recruiting
Site Public Contact · Contact
412-389-5208haneydl@upmc.edu
Heath D. Skinner · Principal Investigator

Lehigh Valley Hospital - Muhlenberg

Bethlehem, Pennsylvania, 18017

Recruiting
Site Public Contact · Contact
610-402-9543Morgan_M.Horton@lvhn.org
Samir Narayan · Principal Investigator

Carlisle Regional Cancer Center

Carlisle, Pennsylvania, 17015

Recruiting
Site Public Contact · Contact
412-339-5294Roster@nrgoncology.org
Heath D. Skinner · Principal Investigator

Pocono Medical Center

East Stroudsburg, Pennsylvania, 18301

Recruiting
Site Public Contact · Contact
610-402-9543Morgan_M.Horton@lvhn.org
Samir Narayan · Principal Investigator

Saint Luke's Hospital-Anderson Campus

Easton, Pennsylvania, 18045

Recruiting
Site Public Contact · Contact
412-339-5294Roster@nrgoncology.org
Diane M. Hershock · Principal Investigator

UPMC Hillman Cancer Center Erie

Erie, Pennsylvania, 16505

Recruiting
Site Public Contact · Contact
412-864-7716ClinicalResearchServices@upmc.edu
Heath D. Skinner · Principal Investigator

UPMC Cancer Center at UPMC Horizon

Farrell, Pennsylvania, 16121

Recruiting
Site Public Contact · Contact
412-339-5294Roster@nrgoncology.org
Heath D. Skinner · Principal Investigator

UPMC Cancer Centers - Arnold Palmer Pavilion

Greensburg, Pennsylvania, 15601

Recruiting
Site Public Contact · Contact
724-838-1900
Heath D. Skinner · Principal Investigator

UPMC Pinnacle Cancer Center/Community Osteopathic Campus

Harrisburg, Pennsylvania, 17109

Recruiting
Site Public Contact · Contact
717-724-6765klitchfield@PINNACLEHEALTH.org
Heath D. Skinner · Principal Investigator

Penn State Milton S Hershey Medical Center

Hershey, Pennsylvania, 17033-0850

Active Not Recruiting

IRMC Cancer Center

Indiana, Pennsylvania, 15701

Recruiting
Site Public Contact · Contact
412-389-5208haneydl@upmc.edu
Heath D. Skinner · Principal Investigator

UPMC-Johnstown/John P. Murtha Regional Cancer Center

Johnstown, Pennsylvania, 15901

Recruiting
Site Public Contact · Contact
814-534-4724
Heath D. Skinner · Principal Investigator

UPMC Cancer Center at UPMC McKeesport

McKeesport, Pennsylvania, 15132

Recruiting
Site Public Contact · Contact
412-647-8073
Heath D. Skinner · Principal Investigator

UPMC Hillman Cancer Center at Rocco And Nancy Ortenzio Cancer Pavilion

Mechanicsburg, Pennsylvania, 17050

Recruiting
Site Public Contact · Contact
412-389-5208haneydl@upmc.edu
Heath D. Skinner · Principal Investigator

UPMC Cancer Center - Monroeville

Monroeville, Pennsylvania, 15146

Recruiting
Site Public Contact · Contact
412-339-5294Roster@nrgoncology.org
Heath D. Skinner · Principal Investigator

UPMC Hillman Cancer Center in Coraopolis

Moon Township, Pennsylvania, 15108

Recruiting
Site Public Contact · Contact
412-389-5208haneydl@upmc.edu
Heath D. Skinner · Principal Investigator

UPMC Cancer Center-Natrona Heights

Natrona Heights, Pennsylvania, 15065

Suspended

UPMC Jameson

New Castle, Pennsylvania, 16105

Suspended

Thomas Jefferson University Hospital

Philadelphia, Pennsylvania, 19107

Recruiting
Site Public Contact · Contact
215-600-9151ONCTrialNow@jefferson.edu
Jennifer M. Johnson · Principal Investigator

Fox Chase Cancer Center

Philadelphia, Pennsylvania, 19111

Recruiting
Site Public Contact · Contact
215-728-4790
Thomas J. Galloway · Principal Investigator

Temple University Hospital

Philadelphia, Pennsylvania, 19140

Recruiting
Site Public Contact · Contact
215-728-2983
Deric C. Savior · Principal Investigator

Allegheny General Hospital

Pittsburgh, Pennsylvania, 15212

Recruiting
Site Public Contact · Contact
877-284-2000
Larisa Greenberg · Principal Investigator

UPMC-Magee Womens Hospital

Pittsburgh, Pennsylvania, 15213

Recruiting
Site Public Contact · Contact
412-647-2811
Heath D. Skinner · Principal Investigator

UPMC-Saint Margaret

Pittsburgh, Pennsylvania, 15215

Recruiting
Site Public Contact · Contact
412-784-4900
Heath D. Skinner · Principal Investigator

UPMC-Shadyside Hospital

Pittsburgh, Pennsylvania, 15232

Recruiting
Site Public Contact · Contact
412-621-2334
Heath D. Skinner · Principal Investigator

UPMC Jefferson Regional Radiation Oncology

Pittsburgh, Pennsylvania, 15236

Suspended

UPMC-Passavant Hospital

Pittsburgh, Pennsylvania, 15237

Recruiting
Site Public Contact · Contact
412-367-6454
Heath D. Skinner · Principal Investigator

UPMC-Saint Clair Hospital Cancer Center

Pittsburgh, Pennsylvania, 15243

Recruiting
Site Public Contact · Contact
412-502-3920
Heath D. Skinner · Principal Investigator

Saint Luke's Hospital - Upper Bucks Campus

Quakertown, Pennsylvania, 18951

Recruiting
Site Public Contact · Contact
610-776-4714
Diane M. Hershock · Principal Investigator

UPMC Cancer Center at UPMC Northwest

Seneca, Pennsylvania, 16346

Recruiting
Site Public Contact · Contact
814-676-7900
Heath D. Skinner · Principal Investigator

Saint Luke's Hospital - Monroe Campus

Stroudsburg, Pennsylvania, 18360

Recruiting
Site Public Contact · Contact
412-339-5294Roster@nrgoncology.org
Diane M. Hershock · Principal Investigator

UPMC Uniontown Hospital Radiation Oncology

Uniontown, Pennsylvania, 15401

Recruiting
Site Public Contact · Contact
724-437-2503
Heath D. Skinner · Principal Investigator

UPMC Washington Hospital Radiation Oncology

Washington, Pennsylvania, 15301

Recruiting
Site Public Contact · Contact
724-223-3788cancer@washingtonhospital.org
Heath D. Skinner · Principal Investigator

Reading Hospital

West Reading, Pennsylvania, 19611

Suspended

Wexford Health and Wellness Pavilion

Wexford, Pennsylvania, 15090

Recruiting
Site Public Contact · Contact
Dawnmarie.DeFazio@ahn.org
Larisa Greenberg · Principal Investigator

AnMed Health Cancer Center

Anderson, South Carolina, 29621

Suspended

Saint Joseph's/Candler - Bluffton Campus

Bluffton, South Carolina, 29910

Active Not Recruiting

Prisma Health Cancer Institute - Spartanburg

Boiling Springs, South Carolina, 29316

Suspended

Medical University of South Carolina

Charleston, South Carolina, 29425

Recruiting
Site Public Contact · Contact
843-792-9321hcc-clinical-trials@musc.edu
Bhishamjit S. Chera · Principal Investigator

Prisma Health Cancer Institute - Faris

Greenville, South Carolina, 29605

Recruiting
Site Public Contact · Contact
864-522-4317Kim.Williams3@prismahealth.org
Emory McTyre · Principal Investigator

Prisma Health Cancer Institute - Eastside

Greenville, South Carolina, 29615

Recruiting
Site Public Contact · Contact
864-522-4317Kim.Williams3@prismahealth.org
Emory McTyre · Principal Investigator

Prisma Health Cancer Institute - Greer

Greer, South Carolina, 29650

Recruiting
Site Public Contact · Contact
864-522-4317Kim.Williams3@prismahealth.org
Emory McTyre · Principal Investigator

Gibbs Cancer Center-Pelham

Greer, South Carolina, 29651

Recruiting
Site Public Contact · Contact
864-560-6104kmertz-rivera@gibbscc.org
Amarinthia (Amy) Curtis · Principal Investigator

Rock Hill Radiation Therapy Center

Rock Hill, South Carolina, 29730

Recruiting
Site Public Contact · Contact
800-804-9376
Benjamin J. Moeller · Principal Investigator

Prisma Health Cancer Institute - Seneca

Seneca, South Carolina, 29672

Recruiting
Site Public Contact · Contact
864-522-4317Kim.Williams3@prismahealth.org
Emory McTyre · Principal Investigator

Spartanburg Medical Center

Spartanburg, South Carolina, 29303

Recruiting
Site Public Contact · Contact
864-560-6104kmertz-rivera@gibbscc.org
Amarinthia (Amy) Curtis · Principal Investigator

Rapid City Regional Hospital

Rapid City, South Dakota, 57701

Active Not Recruiting

Sanford USD Medical Center - Sioux Falls

Sioux Falls, South Dakota, 57117-5134

Recruiting
Site Public Contact · Contact
605-312-3320OncologyClinicalTrialsSF@SanfordHealth.org
Daniel Almquist · Principal Investigator

Vanderbilt University/Ingram Cancer Center

Nashville, Tennessee, 37232

Active Not Recruiting

MD Anderson in The Woodlands

Conroe, Texas, 77384

Recruiting
Site Public Contact · Contact
866-632-6789askmdanderson@mdanderson.org
Neil D. Gross · Principal Investigator

UT Southwestern/Simmons Cancer Center-Dallas

Dallas, Texas, 75390

Active Not Recruiting

University of Texas Medical Branch

Galveston, Texas, 77555-0565

Active Not Recruiting

UT MD Anderson Cancer Center

Houston, Texas, 77030

Recruiting
Site Public Contact · Contact
866-632-6789askmdanderson@mdanderson.org
Neil D. Gross · Principal Investigator

MD Anderson West Houston

Houston, Texas, 77079

Recruiting
Site Public Contact · Contact
877-632-6789askmdanderson@mdanderson.org
Neil D. Gross · Principal Investigator

UT MD Anderson - League City

League City, Texas, 77573

Recruiting
Site Public Contact · Contact
877-632-6789askmdanderson@mdanderson.org
Neil D. Gross · Principal Investigator

UTMB Cancer Center at Victory Lakes

League City, Texas, 77573

Active Not Recruiting

Covenant Medical Center-Lakeside

Lubbock, Texas, 79410

Active Not Recruiting

MD Anderson in Sugar Land

Sugar Land, Texas, 77478

Recruiting
Site Public Contact · Contact
877-632-6789askmdanderson@mdanderson.org
Neil D. Gross · Principal Investigator

Intermountain Medical Center

Murray, Utah, 84107

Active Not Recruiting

Utah Cancer Specialists-Salt Lake City

Salt Lake City, Utah, 84106

Active Not Recruiting

Huntsman Cancer Institute/University of Utah

Salt Lake City, Utah, 84112

Recruiting
Site Public Contact · Contact
888-424-2100cancerinfo@hci.utah.edu
Ying J. Hitchcock · Principal Investigator

Saint George Regional Medical Center

St. George, Utah, 84770

Active Not Recruiting

Dartmouth Cancer Center - North

Saint Johnsbury, Vermont, 05819

Recruiting
Site Public Contact · Contact
800-639-6918cancer.research.nurse@hitchcock.org
Garrett T. Wasp · Principal Investigator

Inova Fairfax Hospital

Falls Church, Virginia, 22042

Active Not Recruiting

Sentara Cancer Institute at Sentara CarePlex Hospital

Hampton, Virginia, 23666

Active Not Recruiting

Sentara Norfolk General Hospital

Norfolk, Virginia, 23507

Active Not Recruiting

VCU Massey Comprehensive Cancer Center

Richmond, Virginia, 23298

Active Not Recruiting

Sentara Virginia Beach General Hospital

Virginia Beach, Virginia, 23454

Active Not Recruiting

Saint Francis Hospital

Federal Way, Washington, 98003

Suspended

Tri-Cities Cancer Center

Kennewick, Washington, 99336

Suspended

PeaceHealth Saint John Medical Center

Longview, Washington, 98632

Recruiting
Site Public Contact · Contact
360-514-2016kmakin-bond@peacehealth.org
Dan S. Zuckerman · Principal Investigator

Skagit Regional Health Cancer Care Center

Mount Vernon, Washington, 98274

Recruiting
Site Public Contact · Contact
360-814-2182rcccclinicalresearch@skagitvalleyhospital.org
Dan S. Zuckerman · Principal Investigator

University of Washington Medical Center - Montlake

Seattle, Washington, 98195

Recruiting
Site Public Contact · Contact
800-804-8824
Cristina P. Rodriguez · Principal Investigator

Spokane Valley Cancer Center-Mayfair

Spokane, Washington, 99208

Suspended

Spokane Valley Cancer Center-Mission

Spokane, Washington, 99216

Suspended

Wenatchee Valley Hospital and Clinics

Wenatchee, Washington, 98801

Recruiting
Site Public Contact · Contact
509-665-5800
Cristina P. Rodriguez · Principal Investigator

West Virginia University Healthcare

Morgantown, West Virginia, 26506

Recruiting
Site Public Contact · Contact
304-293-7374cancertrialsinfo@hsc.wvu.edu
Mohammed Almubarak · Principal Investigator

Camden Clark Medical Center

Parkersburg, West Virginia, 26101

Recruiting
Site Public Contact · Contact
304-293-7374cancertrialsinfo@hsc.wvu.edu
Mohammed Almubarak · Principal Investigator

Wheeling Hospital/Schiffler Cancer Center

Wheeling, West Virginia, 26003

Recruiting
Site Public Contact · Contact
304-243-6442
Mohammed Almubarak · Principal Investigator

Langlade Hospital and Cancer Center

Antigo, Wisconsin, 54409

Recruiting
Site Public Contact · Contact
715-623-9869Juli.Alford@aspirus.org
Christopher S. Platta · Principal Investigator

Saint Vincent Hospital Cancer Center Green Bay

Green Bay, Wisconsin, 54301

Active Not Recruiting

Saint Vincent Hospital Cancer Center at Saint Mary's

Green Bay, Wisconsin, 54303

Active Not Recruiting

University of Wisconsin Carbone Cancer Center - Johnson Creek

Johnson Creek, Wisconsin, 53038

Recruiting
Site Public Contact · Contact
800-622-8922clinicaltrials@cancer.wisc.edu
Paul M. Harari · Principal Investigator

Gundersen Lutheran Medical Center

La Crosse, Wisconsin, 54601

Active Not Recruiting

Mayo Clinic Health System-Franciscan Healthcare

La Crosse, Wisconsin, 54601

Active Not Recruiting

University of Wisconsin Carbone Cancer Center - Eastpark Medical Center

Madison, Wisconsin, 53718

Recruiting
Site Public Contact · Contact
800-622-8922clinicaltrials@cancer.wisc.edu
Paul M. Harari · Principal Investigator

University of Wisconsin Carbone Cancer Center - University Hospital

Madison, Wisconsin, 53792

Recruiting
Site Public Contact · Contact
800-622-8922clinicaltrials@cancer.wisc.edu
Paul M. Harari · Principal Investigator

Bay Area Medical Center

Marinette, Wisconsin, 54143

Active Not Recruiting

Marshfield Medical Center

Marshfield, Wisconsin, 54449

Active Not Recruiting

Froedtert Menomonee Falls Hospital

Menomonee Falls, Wisconsin, 53051

Recruiting
Site Public Contact · Contact
262-257-5100
Musaddiq J. Awan · Principal Investigator

Medical College of Wisconsin

Milwaukee, Wisconsin, 53226

Recruiting
Site Public Contact · Contact
414-805-3666
Musaddiq J. Awan · Principal Investigator

Marshfield Medical Center - Minocqua

Minocqua, Wisconsin, 54548

Active Not Recruiting

Cancer Center of Western Wisconsin

New Richmond, Wisconsin, 54017

Recruiting
Site Public Contact · Contact
952-993-1517mmcorc@healthpartners.com
Charles Shideman · Principal Investigator

Drexel Town Square Health Center

Oak Creek, Wisconsin, 53154

Recruiting
Site Public Contact · Contact
414-805-0505
Musaddiq J. Awan · Principal Investigator

Aspirus Cancer Care - James Beck Cancer Center

Rhinelander, Wisconsin, 54501

Recruiting
Site Public Contact · Contact
715-847-2353Beth.Knetter@aspirus.org
Christopher S. Platta · Principal Investigator

Aspirus Cancer Care - Stevens Point

Stevens Point, Wisconsin, 54481

Active Not Recruiting

Saint Vincent Hospital Cancer Center at Sturgeon Bay

Sturgeon Bay, Wisconsin, 54235-1495

Active Not Recruiting

Aspirus Regional Cancer Center

Wausau, Wisconsin, 54401

Recruiting
Site Public Contact · Contact
877-405-6866
Christopher S. Platta · Principal Investigator

Froedtert West Bend Hospital/Kraemer Cancer Center

West Bend, Wisconsin, 53095

Recruiting
Site Public Contact · Contact
414-805-0505
Musaddiq J. Awan · Principal Investigator

Aspirus Cancer Care - Wisconsin Rapids

Wisconsin Rapids, Wisconsin, 54494

Recruiting
Site Public Contact · Contact
715-422-7718
Christopher S. Platta · Principal Investigator
Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer | Cancerify